The heterogeneity may also be caused by the unstable expression of HER2 during BC progression, including the inconsistency between the primary tumor and matched advanced‐stage biopsy,49 and the discrepancy in HER2 status between primary tumors and matched relapse samples.50 This evidence concerns the gene ERBB2 and neoplasm.